May 22- Amgen Inc said it will terminate a collaboration with AstraZeneca Plc to develop a psoriasis drug after it observed suicidal thoughts in the subjects of a trial. AstraZeneca could decide on the development and marketing of the drug for all territories, except for Japan and certain Asian territories, where Kyowa Hakko Kirin has the rights to it, Amgen said.» Read More
He's expecting a full recovery – and more – for this company.
Pfizer and Nektar Therapeutics said Wednesday clinical trials of the inhaled insulin Exubera found increased cases of lung cancer, leading Nektar to end talks with potential partners to market the product.
CNBC and other media outlets have done a significant amount of reporting on cardiologists' reaction to the Vytorin/Zetia study and the effect the ACC panel's opinion might have on the heart doctors' prescription writing.
European corporate profits for the first quarter of 2008 are expected to hold up, but weaker economic growth resulting from the credit crisis and a stronger euro will take their toll on earnings later in the year.
This morning a little biotech company, Antigenics, announced that Russia has approved its kidney cancer drug Oncophage. It's the first so-called therapeutic cancer vaccine to win full-out approval anywhere in the world.
U.S. private equity firm TPG is planning to announce that it is buying half of SIA Iternational, Russia's largest pharmaceutical distributor, for $800 million, the Wall Street Journal reported on its Web site.
Shares of Wyeth and Elan surged Monday on the promise of a new Alzheimer's drug. Can you trade it?
European shares advanced on Monday, adding to last week's gains, led by financials such as Swiss bank UBS and mining stocks, which gained on the back of higher metals prices and an upbeat analyst note.
The Star-Ledger of New Jersey this weekend did a story that I think provides the best insight and backstory about what happened last week at the highest levels of Schering-Plough.CEO Fred Hassan was in Miami when doctors dropped the bomb on Vytorin and Zetia at the American College of Cardiology meeting.
CEO Fred Hassan updates investors on his company's plans to rebound from the Vytorin debacle.
This week started out with Merck shares suffering their worst loss since the day the drugmaker recalled Vioxx and Schering-Plough shares posting their worst one-day decline ever. But yesterday, SGP had its biggest percentage gain in eight years and today it's finishing the week as the sector's biggest percentage gainer.
Last night while on the elliptical and watching "NBC Nightly News," one spot amid the wall-to-wall commercials for drugs caught my attention. It looks like after 10 years since the first erectile dysfunction pill came on the market--Pfizer's Viagra celebrated a decade since winning FDA approval last week--the makers of Levitra are trying a new marketing tack.
The small biotech company Dendreon put out a press release this morning announcing that an unidentified institutional investor is going to buy eight million shares and warrants to buy as much as another eight million for a total infusion of $47 million.
After the closing bell yesterday, Amgen put out a press release announcing that phase 3 pivotal data are being published in a scientific/medical journal about its most important drug development pipeline product--an osteoporosis drug known as D-mab. (Whenever you see the letters mab at the end of the scientific name for a drug it means it's a monoclonal antibody).
Options activity is picking up in Johnson & Johnson stock. Why?
Investors seem to be shrugging off another setback for drug giant Pfizer. Late yesterday the company announced it's stopping a late-stage clinical trial for a skin cancer drug because it looks like it doesn't work better than chemo.
Walgreen posted a 4.4 percent increase in sales at stores open at least a year as strong demand for Easter merchandise helped offset tepid sales growth for prescription drugs.
Pfizer said on Tuesday it was halting a late stage study of its experimental drug for advanced melanoma after data showed it was no better than standard chemotherapy.
A drug commonly used to fight AIDS appears to nearly double the risk of a heart attack, researchers said Tuesday.
Given investor reaction to the Vytorin/Zetia news yesterday, you might draw the conclusion the huge cholesterol drug franchise might be doomed. Sure, analysts say, prescriptions and sales are gonna go down some more, but they're not going to zero.